Medicinal chemistry–driven discovery of novel SGLT2 inhibitors using integrated in silico approaches

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder that is associated with severe cardiovascular and renal complications. Sodium–glucose co-transporter 2 (SGLT2) inhibitors have emerged as an effective therapeutic class for managing hyperglycemia and its associated comorbidities. In this study, an integrated ligand- and structure-based virtual screening approach was employed to identify novel SGLT2 inhibitors with improved pharmacological profiles. Using the high-resolution cr